| Literature DB >> 2311176 |
J Boas1, D Rasmussen, O P Hansen, S A Engelholm, P Dombernowsky.
Abstract
In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2311176 DOI： 10.1007/bf00686061
Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333